Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Switching to new tenofovir alafenamide keeps virus in check and improves kidney and bone health

People who switch from the current version of tenofovir to tenofovir alafenamide (TAF) – a new formulation that reaches higher levels in HIV-infected cells – maintained undetectable

Published
28 July 2015
By
Liz Highleyman
Raltegravir appears to prevent mother-to-child HIV transmission during late pregnancy

Combination antiretroviral therapy containing the integrase inhibitor raltegravir (Isentress) appears safe and effective and may be an attractive option for treatment for pregnant women with HIV –

Published
28 July 2015
By
Liz Highleyman
Stribild Superior to Boosted Atazanavir in Treatment-Naive Women

Stribild proved virologically superior to atazanavir/ritonavir plus tenofovir/emtricitabine (TDF/FTC) at 48 weeks in WAVES, an international trial in 575 antiretroviral-naive women. No one in the Stribild arm had emergent resistance upon virologic failure, compared with 3 women in the atazanavir arm.

Published
27 July 2015
From
NATAP
'Molecular microscope' finds hidden AIDS virus in the body

Researchers have developed a sophisticated new probe that detects HIV’s hiding places inside and outside of cells. Insights from this high-powered molecular microscope, revealed at an international AIDS conference last week, may clarify critical questions about HIV persistence and, ultimately, about how to rid the body of the virus.

Published
27 July 2015
From
Science
Gay youth PrEP study finds good retention and reasonable adherence

A US study of pre-exposure prophylaxis (PrEP) in 200 young gay and bisexual men aged 18-22 found reasonable levels of adherence. Adherence was highest in those

Published
24 July 2015
By
Gus Cairns
The Day the HIV Treatment Pendulum Stopped Swinging

Normally at scientific conferences, even when study findings are considered to be major, a single researcher stands at a podium for 10 or 15 minutes, takes the audience on a guided PowerPoint tour of charts and graphs, receives a round of applause, and fields a few questions. Then the session moves on to its next topic. The presentation of the START findings was different.

Published
23 July 2015
From
The Body Pro
New NNRTI doravirine suppresses HIV as well as efavirenz but with fewer central nervous system side-effects

Merck's next-generation NNRTI doravirine (formerly known as MK-1439) was found to be as effective as efavirenz at suppressing HIV replication, but half as many study participants taking doravirine experienced drug-related

Published
23 July 2015
By
Liz Highleyman
Same-day start to antiretroviral treatment leads to faster HIV suppression in San Francisco

A programme at San Francisco General Hospital that offers antiretroviral therapy (ART) on the same day as HIV diagnosis led to a high rate of treatment uptake

Published
23 July 2015
By
Liz Highleyman
Africa: MSF Warns Successful Global HIV Response Will Require Bigger Emphasis On Adherence

New MSF report surveying lay counsellor policies across eight countries highlights major weaknesses for adherence support

Published
22 July 2015
From
AllAfrica
Next-generation maturation inhibitor BMS-955176 shows good antiviral activity in combination with atazanavir

The next-generation HIV maturation inhibitor BMS-955176 was well-tolerated and suppressed HIV viral load as well as standard antiretroviral therapy when used in a combination with atazanavir (Reyataz)

Published
22 July 2015
By
Liz Highleyman

Filter by country